Simultaneous RP-HPLC method for the stress degradation studies of atorvastatin calcium and ezetimibe in multicomponent dosage form

Authors

  • A Rajasekaran Department of Pharmaceutical Analysis; KMCH College of Pharmacy, Coimbatore, India
  • R Sasikumar Department of Pharmaceutical Analysis; KMCH College of Pharmacy, Coimbatore, India
  • J Dharuman Department of Pharmaceutical Analysis; KMCH College of Pharmacy, Coimbatore, India

Keywords:

Atorvastatin, Ezetimibe, Degradation, Stress testing, Stability-indicating, Validation

Abstract

A stability-indicating reversed-phase high performance liquid chromatographic (RP-HPLC) method has been developed and validated for simultaneous estimation of atorvastatin calcium and ezetimibe for their multicomponent dosage form. The proposed RP-HPLC method utilizes a 125 mm x 4.6 mm i.d 5 μm Phenomenex C-18 column at ambient temperature; the optimum mobile phase consists of acetonitrile and 0.4% v/v triethylamine (pH adjusted to 5.5 with ortho-phosphoric acid) in the ratio of 55:45, v/v respectively, flow rate of 1.0 ml/min. Measurements were made at a wavelength of 231 nm. Multicomponent dosage form was exposed to thermal, photolytic, hydrolytic and oxidative stress. No co eluting, interfering peaks from excipients, impurities were observed for the degradation products and hence the method was found to be specific. The method was linear in the range of 5-25 μg/ml for atorvastatin calcium and ezetimibe. The mean recoveries were 98.82% and 98.72% for atorvastatin calcium and ezetimibe respectively. The method was validated for linearity, range, precision, accuracy, specificity, selectivity, intermediate precision, ruggedness, robustness, solution stability and suitability.

Downloads

Download data is not yet available.

References

Kracuna M, Kocijana A, Bastardaa A, Graheka R, Plavecb J,

Kocjanb D. Isolation and structure determination of oxidative degradation products of atorvastatin. J. Pharm.Biomed. Anal 2009; 50: 729–736.

El-Moghazy SM, Mohamed MAE, Mohamed MF, Youssef NF.

Development and Validation of HPLC, TLC and Derivative Spectrophotometric Methods for the Analysis of Ezetimibe in the Presence of Alkaline Induced Degradation Products. J. Chin. Chem. Soc 2009; 56: 360-367.

Ballantyne CM, Houri J, Notarbartolo A. Effect of Ezetimibe

Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia. Circulation 2003; 107: 2409-2415.

Koytchev R, Ozalp Y, Erenmemisoglu A, VanderMeer MJ, Alpan

RS. Bioequivalence study of atorvastatin tablets. Arzneim.-Forsch 2004; 54: 573-577.

Bahrami G, Mohammadi B, Mirzaeei S, Kiani A. Determination of atorvastatin in human serum by reversed-phase high-performance liquid chromatography with UV detection. J. Chromatogr. B 2005; 826: 41-45.

Hermann M, Christensen H, Reubsaet JL. Determination

of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC–tandem MS. Anal. Bioanal. Chem 2005; 382: 1242-1249.

Jemal M, Ouyang Z, Chen BC, Teitz D. Quantitation of

the acid and lactone forms of atorvastatin and its biotransformation products in human plasma serum by high-performance liquid chromatography with electrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom 1999; 13: 1003-1015.

Erturk S, Sevinc AE, Ersoy L, Ficicioglu S.An HPLC

method for the determination of atorvastatin and its impurities in bulk drug and tablets. J. Pharm. Biomed. Anal 2003; 33: 1017-1023.

Pasha MK, Muzeeb S, Basha SJ, Shashikumar D, Mullangi R, Srinivas NR. Concurrent determination of ezetimibe and its phase-I and II metabolites by HPLC with UV detection: Quantitative application to various in vitro metabolic stability studies and for qualitative estimation in bile. Biomed. Chromatogr 2006; 20: 282-293.

Raja Rajeswari K, Sankar GG, Rao AL, Seshagirirao JVLN. RP-

HPLC method for the simultaneous determination of Atorvastatin and Amlodipine in tablet dosage form. Indian J Pharm Sci 2006; 68(2): 275-277.

Yadav SS, Mhaske DV, Kakad AB, Patil BD, Kadam

SS, Dhaneshwar SR. Simple and sensitive HPTLC method for the Determination of Content Uniformity of Atorvastatin calcium Tablets. Indian J. Pharm. Sci 2005; 67: 182-186.

Sistla R, Tata VS, Kashyap YV, Chandrasekar D,

Diwan PV. Development and validation of a reversed-phase HPLC method for the determination of ezetimibe in pharmaceutical dosage forms. J. Pharm. Biomed. Anal 2005; 39: 517-522.

Oswald Scheuch S, Siegmund W.A LC–MS/MS method to

quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J. Chromatogr. B 2006; 830: 143-150.

Li S, Liu G, Jia J, Li X, Yu CJ. Liquid chromatography–negative ion electrospray tandem mass spectrometry method for the quantification of ezetimibe in human plasma. J. Pharm. Biomed. Anal 2006; 40: 987-992.

Singh S, Singh B, Bahuguna R, Wadhwa L, Saxena R. Stress

degradation studies on ezetimibe and development of a validated stability-indicating HPLC assay. J. Pharm. Biomed. Anal 2006; 41: 1037-1040.

Zeaiter M, Roger JM, Maurel VB, Rutledge DN. Robustness of

models developed by multivariate calibration. Part I: The assessment of robustness. Trends Anal. Chem 2004; 23: 157.

Mulholland M. Ruggedness testing in analytical chemistry.

Trends Anal. Chem 1988; 7: 383.

Heyden YV, Nijhuis A, Verbeke JS, Vandeginste BGM, Massaret DL. Guidance for robustness/ruggedness tests in method validation. J. Pharm.Biomed. Anal 2001; 24: 723.

Downloads

Published

2011-09-20

How to Cite

1.
Rajasekaran A, Sasikumar R, Dharuman J. Simultaneous RP-HPLC method for the stress degradation studies of atorvastatin calcium and ezetimibe in multicomponent dosage form. Ars Pharm [Internet]. 2011 Sep. 20 [cited 2024 Jul. 22];52(3):12-8. Available from: https://revistaseug.ugr.es/index.php/ars/article/view/4739

Issue

Vol. 52 No. 3 (2011)

Section

Original Articles

License

The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:

  1. The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.

b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.

c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).